New hope for blistering skin diseases: drug targets antibodies to heal wounds

This early-phase study tests whether the drug efgartigimod (VYVGART) can lower harmful collagen VII antibodies and improve wound healing in people with two rare blistering skin conditions: recessive dystrophic epidermolysis bullosa (RDEB) and epidermolysis bullosa acquisita (EBA). About 18 participants aged 12 and older will receive the drug intravenously, and those with RDEB will also receive a topical gene therapy (VYJUVEK) on one wound. The goal is to see if reducing these antibodies leads to fewer wounds and better quality of life.